Skip to content

house · Committee report

H. Rept. 118-165

GABRIELLA MILLER KIDS FIRST RESEARCH ACT 2.0

2023-08-25

Committees

Associated legislation

Text

Purpose and Summary

The bill reauthorizes funding for the National Institute of Health's (NIH) Gabriella Miller Kids First Pediatric Research Program. The bill also requires coordinating federal efforts related to pediatric cancer research, as well as a report detailing current federally funded programs and initiatives, and the advancements made.

Background and Need for Legislation

The Gabriella Miller Kids First Pediatric Research Program (Kids First) was created to facilitate additional research and education around the relationship between childhood cancer and structural birth defects, and the shared genetic pathways between these disorders. It is estimated that over 9,910 children in the United States under the age of 15 will be diagnosed with cancer in 2023.\1\ At the same time, one in 33 infants born in the United States has a birth defect. Birth defects are the leading cause of death during the first year of life, and account for half of all pediatric hospitalizations.\2\ Research has shown that children with birth defects have an increased risk of developing childhood cancer. This suggests there are shared genetic pathways underlying some types of childhood cancer and structural birth defects, though more coordinated research and a better understanding of the role of genetics is needed. --------------------------------------------------------------------------- \1\Key Statistics for Childhood Cancers, American Cancer Society, https://www.cancer.org/ cancer/types/cancer-in children/key-statistics.html. \2\Overview, Gabriella Miller Kids First Pediatric Research Program (Kids First), NIH, https://commonfund.nih.gov/kidsfirst/overview. ---------------------------------------------------------------------------

Committee Action

On June 14, 2023, the Subcommittee on Health held a hearing on H.R. 3391. The Subcommittee received testimony from: Dr. Elizabeth Cherot, MD, MBA, Senior Vice President and Chief Medical Health Officer, March of Dimes; Dr. Alexis A. Thompson, MD, MPH, Chief of Division of Hematology, Elias Schwartz MD Endowed Chair in Hematology, Children's Hospital of Philadelphia, Professor of Pediatrics, University of Pennsylvania Perelman School of Medicine; Dr. Meredithe McNamara, MD, MS, FAAP, Assistant Professor, Yale School of Medicine; Dr. Miriam Grossman, MD, Child, Adolescent, and Adult Psychiatrist; Mr. George Manahan, Parkinson's Advocate and Patient; and, Mr. Kevin O'Connor, Assistant to the General President for Government Affairs and Political Action, International Association of Fire Fighters. On, July 13, 2023, the Subcommittee on Health met in open markup session and forwarded H.R. 3391, as amended, to the full Committee by a record vote of 27 yeas and 0 nays. On July 19, 2023, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 3391, as amended, favorably reported to the House by a record vote of 50 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 3391 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to facilitate research and education around the relationship between childhood cancer and structural birth defects by reauthorizing funding for the National Institute of Health's Gabriella Miller Kids First Pediatric Research Program and coordinating federal efforts related to pediatric cancer research. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 3391 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 3391: On June 14, 2023, the Subcommittee on Health held a hearing on H.R. 3391. The Subcommittee received testimony from: Dr. Elizabeth Cherot, MD, MBA, Senior Vice President and Chief Medical Health Officer, March of Dimes; Dr. Alexis A. Thompson, MD, MPH, Chief of Division of Hematology, Elias Schwartz MD Endowed Chair in Hematology, Children's Hospital of Philadelphia, Professor of Pediatrics, University of Pennsylvania Perelman School of Medicine; Dr. Meredithe McNamara, MD, MS, FAAP, Assistant Professor, Yale School of Medicine; Dr. Miriam Grossman, MD, Child, Adolescent, and Adult Psychiatrist; Mr. George Manahan, Parkinsons Advocate and Patient; and, Mr. Kevin O'Connor, Assistant to the General President for Government Affairs and Political Action, International Association of Fire Fighters. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 3391 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides a short title of ``Gabriella Miller Kids First Research Act 2.0''. Section 2. Funding for the pediatric research initiative Section 2 amends section 402 of the Public Health Service Act to extend funding for the Division of Program Coordination, Planning, and Strategic Initiatives for fiscal years 2024 through 2028. Section 3. Coordination of NIH funding for pediatric research Section 3 expresses the sense of Congress that the Director of the National Institutes of Health oversee and coordinate pediatric research supported by the NIH and amends section 402 of the Public Health Service Act to clarify pediatric research should not duplicate existing research activities of the NIH. Section 4. Report on progress and investment in pediatric research Section 4 directs the Secretary of Health and Human Services to submit a report no later than 5 years after the bill's enactment detailing current federally funded pediatric research programs and initiatives and advancements made. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): PUBLIC HEALTH SERVICE ACT * * * * * * * TITLE IV--NATIONAL RESEARCH INSTITUTES Part A--National Institutes of Health * * * * * * * appointment and authority of director of nih Sec. 402. (a) The National Institutes of Health shall be headed by the Director of NIH who shall be appointed by the President by and with the advice and consent of the Senate. The Director of NIH shall perform functions as provided under subsection (b) and as the Secretary may otherwise prescribe. (b) In carrying out the purposes of section 301, the Secretary, acting through the Director of NIH-- (1) shall carry out this title, including being responsible for the overall direction of the National Institutes of Health and for the establishment and implementation of general policies respecting the management and operation of programs and activities within the National Institutes of Health; (2) shall coordinate and oversee the operation of the national research institutes, national centers, and administrative entities within the National Institutes of Health; (3) shall, in consultation with the heads of the national research institutes and national centers, be responsible for program coordination across the national research institutes and national centers, including conducting priority-setting reviews, to ensure that the research portfolio of the National Institutes of Health is balanced and free of unnecessary duplication, and takes advantage of collaborative, cross-cutting research; (4) shall assemble accurate data to be used to assess research priorities, including-- (A) information to better evaluate scientific opportunity, public health burdens, and progress in reducing health disparities; and (B) data on study populations of clinical research, funded by or conducted at each national research institute and national center, which-- (i) specifies the inclusion of-- (I) women; (II) members of minority groups; (III) relevant age categories, including pediatric subgroups; and (IV) other demographic variables as the Director of the National Institutes of Health determines appropriate; (ii) is disaggregated by research area, condition, and disease categories; and (iii) is to be made publicly available on the Internet website of the National Institutes of Health; (5) shall ensure that scientifically based strategic planning is implemented in support of research priorities as determined by the agencies of the National Institutes of Health, and through the development, implementation, and updating of the strategic plan developed under subsection (m); (6) shall ensure that the resources of the National Institutes of Health are sufficiently allocated for research projects identified in strategic plans; (7)(A) shall, through the Division of Program Coordination, Planning, and Strategic Initiatives-- (i) identify research that represents important areas of emerging scientific opportunities, rising public health challenges, or knowledge gaps that deserve special emphasis and would benefit from conducting or supporting additional research that involves collaboration between 2 or more national research institutes or national centers, or would otherwise benefit from strategic coordination and planning; (ii) include information on such research in reports under section 403; and (iii) in the case of such research supported with funds referred to in subparagraph (B)-- (I) require as appropriate that proposals include milestones and goals for the research; (II) require that the proposals include timeframes for funding of the research; and (III) ensure appropriate consideration of proposals for which the principal investigator is an individual who has not previously served as the principal investigator of research conducted or supported by the National Institutes of Health; (B)(i) may, with respect to funds reserved under section 402A(c)(1) for the Common Fund, allocate such funds to the national research institutes and national centers for conducting and supporting research that is identified under subparagraph (A); and (ii) shall, with respect to funds appropriated to [the Common Fund] the Division of Program Coordination, Planning, and Strategic Initiatives pursuant to section 402A(a)(2), allocate such funds to the national research institutes and national centers for making grants for pediatric research that is identified under subparagraph (A) and shall prioritize, as appropriate, such pediatric research that does not duplicate existing research activities of the National Institutes of Health; and (C) may assign additional functions to the Division in support of responsibilities identified in subparagraph (A), as determined appropriate by the Director; (8) shall, in coordination with the heads of the national research institutes and national centers, ensure that such institutes and centers-- (A) preserve an emphasis on investigator- initiated research project grants, including with respect to research involving collaboration between 2 or more such institutes or centers; (B) when appropriate, maximize investigator- initiated research project grants in their annual research portfolios; (C) foster collaboration between clinical research projects funded by the respective national research institutes and national centers that-- (i) conduct research involving human subjects; and (ii) collect similar data; and (D) encourage the collaboration described in subparagraph (C) to-- (i) allow for an increase in the number of subjects studied; and (ii) utilize diverse study populations, with special consideration to biological, social, and other determinants of health that contribute to health disparities; (9) shall ensure that research conducted or supported by the National Institutes of Health is subject to review in accordance with section 492 and that, after such review, the research is reviewed in accordance with section 492A(a)(2) by the appropriate advisory council under section 406 before the research proposals are approved for funding; (10) shall have authority to review and approve the establishment of all centers of excellence recommended by the national research institutes; (11)(A) shall oversee research training for all of the national research institutes and National Research Service Awards in accordance with section 487; and (B) may conduct and support research training-- (i) for which fellowship support is not provided under section 487; and (ii) that does not consist of residency training of physicians or other health professionals; (12) may, from funds appropriated under section 402A(b), reserve funds to provide for research on matters that have not received significant funding relative to other matters, to respond to new issues and scientific emergencies, and to act on research opportunities of high priority; (13) may, subject to appropriations Acts, collect and retain registration fees obtained from third parties to defray expenses for scientific, educational, and research-related conferences; (14) for the national research institutes and administrative entities within the National Institutes of Health-- (A) may acquire, construct, improve, repair, operate, and maintain, at the site of such institutes and entities, laboratories, and other research facilities, other facilities, equipment, and other real or personal property, and (B) may acquire, without regard to the Act of March 3, 1877 (40 U.S.C. 34), by lease or otherwise through the Administrator of General Services, buildings or parts of buildings in the District of Columbia or communities located adjacent to the District of Columbia for use for a period not to exceed ten years; (15) may secure resources for research conducted by or through the National Institutes of Health; (16) may, without regard to the provisions of title 5, United States Code, governing appointments in the competitive service, and without regard to the provisions of chapter 51 and subchapter III of chapter 53 of such title relating to classification and General Schedule pay rates, establish such technical and scientific peer review groups and scientific program advisory committees as are needed to carry out the requirements of this title and appoint and pay the members of such groups, except that officers and employees of the United States shall not receive additional compensation for service as members of such groups; (17) may secure for the National Institutes of Health consultation services and advice of persons from the United States or abroad; (18) may use, with their consent, the services, equipment, personnel, information, and facilities of other Federal, State, or local public agencies, with or without reimbursement therefor; (19) may, for purposes of study, admit and treat at facilities of the National Institutes of Health individuals not otherwise eligible for such treatment; (20) may accept voluntary and uncompensated services; (21) may perform such other administrative functions as the Secretary determines are needed to effectively carry out this title; (22) may appoint physicians, dentists, and other health care professionals, subject to the provisions of title 5, United States Code, relating to appointments and classifications in the competitive service, and may compensate such professionals subject to the provisions of chapter 74 of title 38, United States Code; (23) shall designate a contact point or office to help innovators and physicians identify sources of funding available for pediatric medical device development; (24) implement the Cures Acceleration Network described in section 480; (25) may require recipients of National Institutes of Health awards to share scientific data, to the extent feasible, generated from such National Institutes of Health awards in a manner that is consistent with all applicable Federal laws and regulations, including such laws and regulations for the protection of-- (A) human research participants, including with respect to privacy, security, informed consent, and protected health information; and (B) proprietary interests, confidential commercial information, and the intellectual property rights of the funding recipient; (26) shall consult with the Assistant Secretary for Preparedness and Response, the Director of the Biomedical Advanced Research and Development Authority, the Director of the Centers for Disease Control and Prevention, and the heads of other Federal agencies and offices, as appropriate, regarding research needs to advance medical countermeasures to diagnose, mitigate, prevent, or treat harm from any biological agent or toxin, including emerging infectious diseases, chemical, radiological, or nuclear agent that may cause a public health emergency or other research needs related to emerging public health threats; (27) shall consult with the Director of the Office of National Security within the Department of Health and Human Services, the Assistant Secretary for Preparedness and Response, the Director of National Intelligence, the Director of the Federal Bureau of Investigation, and the heads of other appropriate agenci

Source: https://api.congress.gov/v3/committee-report/118/hrpt/165